| Previous Close | 38.16 |
| Open | 38.41 |
| Bid | 38.39 x 1400 |
| Ask | 38.56 x 3200 |
| Day's Range | 38.21 - 38.66 |
| 52 Week Range | 31.43 - 48.25 |
| Volume | 3,100,857 |
| Avg. Volume | 4,980,891 |
| Market Cap | 97.284B |
| Beta (5Y Monthly) | 0.32 |
| PE Ratio (TTM) | 38.78 |
| EPS (TTM) | 0.99 |
| Earnings Date | Feb. 01, 2017 - Feb. 06, 2017 |
| Forward Dividend & Yield | 2.03 (5.27%) |
| Ex-Dividend Date | Nov. 12, 2020 |
| 1y Target Est | 48.50 |
- Zacks
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.
- Yahoo Finance UK
The 50 best places to work in the UK in 2021
Glassdoor’s Employees’ Choice Awards features a list of business across a range of sectors, including finance, manufacturing, pharmaceuticals, insurance, technology and food.
- Motley Fool
Why Vir Biotechnology Stock Vaulted Higher Today
Shares of Vir Biotechnology (NASDAQ: VIR) were vaulting 12.8% higher as of 3:07 p.m. EST on Tuesday. The big jump came after the company announced news about separate collaborations with Gilead Sciences (NASDAQ: GILD) and GlaxoSmithKline (NYSE: GSK). Vir and Gilead plan to work together on a phase 2 study evaluating Vir's VIR-2218 with Gilead's selgantolimod in treating individuals infected with the hepatitis B virus (HBV).
